Description
Molecular point-of-care (mPOC) diagnostics are revolutionizing the in vitro diagnostics (IVD) landscape, delivering the sensitivity and specificity of molecular testing with the accessibility and speed of traditional point-of-care (POC) solutions. Kalorama Information’s latest report, Molecular Point-of-Care (mPOC) Market Outlook and Innovations, 2024-2029, provides a comprehensive analysis of this rapidly evolving market, covering the size, growth trajectory, and competitive dynamics forecasted over a five year span to 2029.
Market Drivers & Opportunities
mPOC has transitioned from an emerging innovation to a major market force, driven by increasing demand for rapid and accurate diagnostic solutions in critical care units, outpatient clinics, physician offices, and community health settings. The COVID-19 pandemic accelerated adoption, particularly in the respiratory testing segment, but the market continues to expand into new areas, including hospital-acquired infections (HAIs), sexually transmitted infections (STIs), and tropical diseases.
With leading companies such as Abbott, Cepheid, bioMérieux, Roche, and QuidelOrtho competing in the space, this report explores key questions:
- What is the size and projected growth of the mPOC market?
- Which companies are leading the market, and how are they positioned?
- How is mPOC impacting traditional laboratory-based molecular testing?
- What regions and disease segments present the greatest opportunities?
Comprehensive Market Insights
This report offers detailed segmentation of the mPOC market, including:
- Market Sizing & Forecasts (2024-2029) – Revenue projections by technology, region, and disease area.
- Competitive Analysis – Market share breakdowns and insights into leading companies.
- Geographic Trends – Market distribution across North America, Europe, Asia Pacific, and the Rest of the World.
- Technology & Regulatory Landscape – Overview of CLIA-waived and moderate-complexity molecular platforms.
Scope
Molecular Point-of-Care (mPOC) Market Outlook and Innovations, 2024-2029 provides market sizing, forecasting, trend mapping, and competitive analysis for POC tests using PCR or other molecular technology, offering fast turnaround times and usability in near-patient settings. This Kalorama Information report provides real-world analysis and modeling for relevant circumstances, with insights into near-patient molecular testing using small instruments.
This comprehensive analysis includes market shares for companies, regions, and disease types, distinguishing between “true” molecular point-of-care and near-patient molecular systems. The report highlights the competitive landscape, with major IVD companies and innovative players contributing to the market’s growth. The report defines molecular point-of-care (mPOC) devices as those that run PCR or other DNA and RNA testing on a portable device, with features such as small footprint, fast result times, and usability outside of a reference lab.
A Decade of mPOC Research Expertise
Kalorama Information has been covering the mPOC market since its inception and provides real-world analysis rooted in extensive primary and secondary research. Whether you are an IVD company, investor, or healthcare provider Molecular Point-of-Care (mPOC) Market Outlook and Innovations, 2024-2029, offers critical insights to help you navigate and capitalize on this fast-growing segment.
Table of Contents
Chapter 1: Executive Summary
- Figure 1-1: Molecular Point-of-Care Market, 2024-2029 ($ million)
- Figure 1-2: Near Patient Molecular Systems Market, 2024-2029 ($ million)
Where is Molecular Point-of-Care in 2025?
- Table 1-1: Molecular Point-of-Care Market, 2024-2029 ($ million)
Molecular Point-of-Care Market Analysis
- Table 1-2: Molecular Point-of-Care Market Growth, 2024-2029 (%)
- Figure 1-3: Molecular Point-of-Care Market, by Disease Indication, 2024 (%) [COVID/Respiratory, Other]
Market Observations
“Near-Patient” Molecular Systems Market
- Table 1-3: Near Patient Molecular Systems Market, 2024-2029 ($ million)
- Table 1-4: Near Patient Molecular Systems Market Growth, 2024-2029 (%)
- Table 1-5: mPOC and Near-Patient Market, 2024-2029 ($ million)
- Figure 1-4: mPOC and Near-Patient Market, 2024-2029 ($ million)
Current Trends
Molecular Point-of-Care Diagnostics Defined
Usage of Molecular Point-of-Care
Leading mPOC Platforms
- Table 1-6: Molecular POC Diagnostic Platforms and Technologies
Trends
Scope and Methodology
Chapter 2: Molecular Point-of-Care Market Development and Trends
COVID-19 and Molecular POC
- Table 2-1: Molecular POC COVID-19 Emergency Authorizations
CDC Initial Response, Long Term Situation
COVID-19’s Unique Challenge
BARDA Directs Funding to mPOC
Regulatory Developments
Consortia, Funding, Prizes
Deals
- Table 2-2: Deals in Molecular Point-of-Care, April 2019-Feb 2025
Advantages and Disadvantages of Molecular Point-of-Care
- Table 2-3: Disadvantages of Molecular Point-of-Care, by Setting [Physician Office Laboratory (POL) / Other Outpatient Settings, Developing and Low-Resource Areas, and Hospital POC]
Justification: The Sensitivity/Specificity Argument
New Systems and Menu Expansion
New Systems Introduced in Development
Combination Tests Changing Market: SARS-CoV-2, Flu A, Flu B, and RSV
STI Continues to Be a Growth Area
Deals, Investment in mPOC Systems
Roche Acquires LumiraDx for up to $350 Million
Thermo Acquires Mesa Biotech
China as a POC Market
Common Tests and Analytes in POC Diagnostics
Component Technologies of Molecular Point-of-Care Diagnostics
Microfluidics
qPCR
Microarrays
Isothermal Amplification
Test Automation
Primers and Probes
Detection
Next-Generation Sequencing
Molecular Diagnostics
Real-Time PCR (qPCR)
Isothermal Amplification Methods
Loop-Mediated Isothermal Amplification (LAMP)
Nicking Enzyme Amplification Reaction (NEAR)
Strand Displacement Amplification (SDA)
Helicase Dependent Amplification (HDA)
Nucleic Acid Sequence-Based Amplification (NASBA)
Transcription-Mediated Amplification (TMA)
Cross Priming Amplification (CPA)
Line Probe Assays
Applications and Potential Applications for Molecular Point-of-Care
Major Testing Applications for Molecular POC Diagnostics
Influenza
Reclassification of RIDTs
Hospital-Acquired Infections (HAIs)
Strep A
Respiratory Syncytial Virus (RSV)
Emerging Applications
Zika
Other Respiratory Infections
Group B Streptococcus
Human Papillomavirus
Herpes Simplex Virus
Vaginitis
Tuberculosis
Malaria
Other Tropical and Neglected Diseases
Cancer
European Device Regulations
Chapter 3: Market Analysis
Molecular Point-of-Care Market Analysis
- Table 3-1: Molecular Point-of-Care Market, 2024-2029 ($ million) (%)
- Figure 3-1: Molecular Point-of-Care Market, 2024-2029 ($ million)
Regional Shares
- Table 3-2: Geographic Breakout of the Molecular Point-of-Care Market, by Region, 2024 ($ million) [APAC, Europe, North America, Rest of World]
- Figure 3-2: Geographic Breakout of the Molecular Point-of-Care Market, by Region, 2024 ($ million) [APAC, Europe, North America, Rest of World]
- Figure 3-3: Global Molecular Point-of-Care Market Share, by Region, 2024 ($ million) [APAC, Europe, North America, Rest of World]
Breakout by Disease Area
- Table 3-3: Segment Breakout of Molecular Point-of-Care Market, by Disease Indication, 2024 ($ million) [COVID/Respiratory, Other]
- Figure 3-4: Segment Breakout of Molecular Point-of-Care Market, by Disease Indication, 2024 ($ million) [COVID/Respiratory, Other]
- Figure 3-5: Breakout of Molecular Point-of-Care Market Share, by Disease Indication, 2024 (%) [COVID/Respiratory, Other]
“Near Patient Molecular” Market
- Table 3-4: Near Patient Molecular Point-of-Care Market, 2024-2029 ($ million) (%)
- Figure 3-6: Near Patient Molecular Point-of-Care Market, 2024-2029 ($ million)
Vendor Market Share for Near Patient Molecular Testing
- Table 3-5: Near Patient Molecular Testing Market Share, by Vendor, 2024 (%) [Abbott, bioMérieux, Cepheid, Roche, Other]
- Figure 3-7: Near Patient Molecular Testing Market Share, by Vendor, 2024 (%) [Abbott, bioMérieux, Cepheid, Roche, Other]
Chapter 4: Company Profiles
Abbott Laboratories
Aidian Oy
Akonni Biosystems
binx health, inc.
Biocartis NV
bioMérieux SA
- Table 4-1: bioMérieux FilmArray Est. Systems per Quarter, Q4 ’18-Q4 ’24
- Figure 4-1: FilmArray Systems Installed by Quarter, Q4 2018-Q4 2024
Cepheid (Danaher)
Molecular Healthcare-Acquired Infection (HAI) Testing
Molecular Sexual Health and Women’s Health Testing
Molecular Critical Infectious Disease Testing
Molecular Oncology/Genetics Testing
Credo Diagnostics Biomedical Pte. Ltd.
Curetis NV (OpGen)
DiaSorin S.p.A
GenMark Diagnostics (Roche)
Greiner Bio-One GmbH
Lucira Health (Pfizer)
Meridian Bioscience, Inc. (SD Biosensor)
Mesa Biotech, Inc. (Thermo)
QIAGEN NV
QuantuMDx Group
QuidelOrtho Corporation
Roche
Sekisui Diagnostics LLC
T2 Biosystems
